Seres Therapeutics announced late-breaking data from its Phase III ECOSPOR III study evaluating SER 109, an investigational oral microbiome therapeutic for recurrent C. difficile infection (rCDI).
A Phase III study to evaluate the efficacy and safety of Cimzia (certolizumab pegol), from UCB, in combination with methotrexate...
Patient dosing and screening has begun in two new Phase III clinical trials testing TMC 435, from Medivir/Tibotec, in Hepatitis...
Top-line results from three pivotal Phase III trials examining TMC 435 (simeprevir, from Medivir/Tibotec, administered with pegylated interferon and ribavirin...
Seres Therapeutics reported positive topline results from the pivotal Phase III ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER 109 for recurrent C. difficile infection (CDI). The study showed that SER 109 administration resulted in a highly statistically significant absolute decrease of 30.2% in the proportion of patients who experienced a recurrence in CDI
BMS announced Phase III results from the global HALLMARK-Dual study investigating the all-oral, interferon- and ribavirin-free regimen of daclatasvir (DCV),...
Boehringer Ingelheim announced that enrollment has commenced at North American sites in its pivotal Phase III clinical trial program for...
Seres Therapeutics announced the presentation of its final 24-week data from the pivotal Phase III ECOSPOR III study evaluating SER 109, an investigational oral microbiome therapy for recurrent C. difficile infection (rCDI).
Amgen announced that the Phase III TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating evolocumab...
Alnylam Pharmaceuticals, Inc. announced that the Company has initiated ILLUMINATE-C, a new global Phase III study of lumasiran, an investigational,...